? CANCER PREVENTION AND CONTROL PROGRAM The Cancer Prevention and Control (CPC) Program, led by Clapper and Fang, is comprised of 25 Primary Members and 8 Collaborating Members. Program funding is $9M (project direct costs) annually, including $7.8M in peer-reviewed funding of which $5M is from the NCI. CPC members have been highly productive and interactive during the past funding cycle, generating 614 publications, with 16% representing intra- programmatic and 27% representing inter-programmatic collaborations. The scientific mission of the CPC Program is to reduce the morbidity and mortality associated with cancer by focusing on the prevention and control of cancer in defined populations known to be at increased risk for cancer. The Program has three overarching themes: 1) To identify factors (host, genetic, environmental) that contribute to cancer risk and/or serve as biomarkers for risk assessment and early detection [Risk Assessment theme]; 2) To develop and evaluate strategies to enhance risk communication and decision- making [Risk Communication theme]; and 3) To develop and evaluate strategies to modify risk and enhance outcomes among at-risk individuals and cancer patients [Risk Modification theme]. Efforts to successfully realize each of these themes benefit from the activities of multidisciplinary teams working together in a coordinated fashion to identify and address the complex factors that contribute to and/or influence cancer risk, risk communication and decision making, and patient and population outcomes. The scientific themes of the CPC Program are pursued by faculty members who have expertise in diverse fields including molecular biology, oncology, psychology, medicine, public health, pathology, bioinformatics, health services research, and epidemiology. These collaborative efforts result in a productive research environment that fosters the identification of new biomarkers of cancer risk and novel molecular targets for preventive intervention, and the successful development and implementation of novel, state-of-the-art approaches for reducing cancer risk and enhancing outcomes in at-risk populations, cancer patients, and their family members. The CPC Program serves as a primary conduit via which to translate research findings to the surrounding communities, and efforts across the three themes actively address the cancer burden among minority and other underserved populations in the catchment area. CPC Program members have successfully accrued 12,246 research participants to interventional and non-interventional studies during the past 4-year period (2011-2014) and utilized all 12 of the CCSG-supported Shared Resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA006927-53S1
Application #
9754650
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Lin, Alison J
Project Start
Project End
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
53
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Fareed, Muhammad M; Eldib, Ahmed; Weiss, Stephanie E et al. (2018) A treatment planning comparison between a novel rotating gamma system and robotic linear accelerator based intracranial stereotactic radiosurgery/radiotherapy. Phys Med Biol 63:035029
Bleicher, Richard J (2018) Timing and Delays in Breast Cancer Evaluation and Treatment. Ann Surg Oncol 25:2829-2838
Bai, Tian; Chanda, Ashis Kumar; Egleston, Brian L et al. (2018) EHR phenotyping via jointly embedding medical concepts and words into a unified vector space. BMC Med Inform Decis Mak 18:123
Mehrazin, Reza; Dulaimi, Essel; Uzzo, Robert G et al. (2018) The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma. Ther Adv Urol 10:3-10
Tang, Baiqing; Lee, Hyung-Ok; An, Serim S et al. (2018) Specific Targeting of MTAP-Deleted Tumors with a Combination of 2'-Fluoroadenine and 5'-Methylthioadenosine. Cancer Res 78:4386-4395
Fang, Carolyn Y; Tseng, Marilyn (2018) Ethnic density and cancer: A review of the evidence. Cancer 124:1877-1903
Malik, R; Luong, T; Cao, X et al. (2018) Rigidity controls human desmoplastic matrix anisotropy to enable pancreatic cancer cell spread via extracellular signal-regulated kinase 2. Matrix Biol :
Giri, Veda N; Obeid, Elias; Hegarty, Sarah E et al. (2018) Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling. Prostate 78:879-888
Anari, Fern; O'Neill, John; Choi, Woonyoung et al. (2018) Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. Eur Urol Oncol 1:54-60
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739

Showing the most recent 10 out of 1280 publications